Zheng Quan Zhi Xing·2025-03-25 13:33Core Viewpoint - The company has developed a "Quality Improvement and Efficiency Enhancement Return to Shareholders" action plan for 2025, aiming to enhance operational efficiency, strengthen market competitiveness, and improve its image in the capital market [1] Group 1: Business Focus and Innovation - The company focuses on its core business of developing, producing, and commercializing innovative vaccines that meet both Chinese and international standards, achieving a revenue of approximately 793.79 million yuan, a 41.31% increase year-on-year [1] - The company plans to continue promoting its unique quadrivalent meningococcal vaccine, MCV4, and has submitted an application to expand its age coverage, which, once approved, will enhance its market presence [1] - The company is also preparing for the commercialization of its product PCV13i, having completed clinical site inspections and is actively engaging with regulatory authorities to ensure smooth approval processes [2] Group 2: International Strategy and Market Expansion - The company's international strategy is based on a "full value chain layout," establishing local production bases in countries like Pakistan, Mexico, and Malaysia to meet public health needs [3] - The company aims to explore the feasibility of product procurement by international organizations and is preparing for WHO PQ certification to enhance its global market access [3] Group 3: Corporate Governance and Shareholder Returns - The company is committed to improving corporate governance and internal control systems to ensure compliance and protect shareholder rights [4] - A three-year shareholder dividend plan has been established, with cash dividends amounting to approximately 198 million yuan since its listing, and a share buyback of 683,748 shares, representing about 0.2763% of total shares [5] Group 4: Investor Relations and Communication - The company actively engages with investors through various channels, including performance briefings and investor open days, to communicate its operational and financial status [6] - The first investor open day was held in November 2024, where management shared insights on vaccine development and future strategies [6] Group 5: ESG Commitment - The company plans to enhance its ESG performance and reporting in line with regulatory requirements, aiming to address stakeholder expectations regarding sustainability [6] Group 6: Responsibility and Compliance - The company emphasizes the importance of compliance among its key personnel and has organized training to enhance their understanding of regulations and responsibilities [7] - Continuous evaluation of the action plan will be conducted to ensure focus on core competencies and risk management [7]